Polat Asude Kara, Belli Asli Akin, Karakus Volkan, Dere Yelda
Department of Dermatology, Istanbul Training and Research Hospital - Istanbul, Turkey.
Department of Dermatology, Mugla Sitki Kocman University Training and Research Hospital - Mugla, Turkey.
An Bras Dermatol. 2017;92(5 Suppl 1):59-61. doi: 10.1590/abd1806-4841.20176688.
Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.
地拉罗司是一种铁螯合剂，用于治疗铁过载疾病，如地中海贫血和骨髓增生异常综合征。尽管地拉罗司的大多数不良反应涉及胃肠道症状以及血清肌酐和转氨酶升高，但皮疹，如斑丘疹和荨麻疹样皮疹也有报道。本研究报告了1例因使用地拉罗司治疗而发生荨麻疹性血管炎的骨髓增生异常综合征病例。通过激发试验以及组织病理学和临床检查结果确诊为药物疹。据我们所知，我们报告了首例地拉罗司诱发的荨麻疹性血管炎病例。医生应意识到地拉罗司治疗可能引发荨麻疹性血管炎，以及停药通常会使病情改善这一事实。
